About Phapros
Phapros is a publicly listed company based in Jakarta (Indonesia) founded in 1954, and was acquired by Kimia Farma in February 2019. Pharmaceuticals and medical devices are manufactured and exported by Phapros. Its website phapros.co.id draws about 14 thousand monthly visits. Its focus areas include Traditional Pharmaceuticals. Its legal entity is PT Phapros Tbk.
Company details
Founded in 1954, Phapros operates in the pharmaceutical sector from Jakarta, Indonesia. Branded and generic prescription drugs, over-the-counter medications, and medical devices are produced across the value chain, including research, development, manufacturing, and distribution. Contract manufacturing services are provided, and products are exported internationally. As a subsidiary of a larger pharmaceutical entity, operations emphasize quality standards in healthcare supplies.
- Headquarters Jakarta, Indonesia
- Stage Acquired
- SectorsHealthcare
- Website category Computers Electronics and Technology · Search Engines
- Email••••••••
- Phone•••• ••••
- Website phapros.co.id
- Social LinkedIn X Facebook Instagram
- Acquired by Kimia Farma (Feb 2019)
- Legal Name Pt Phapros Tbk
- Annual Revenue$56.29 M (USD)26.34as on Dec 31, 2025
- Net Profit$1.68 M (USD)as on Dec 31, 2025
- EBITDA$8.14 M (USD)as on Dec 31, 2025
- Investors
- Acquired byKimia Farma
(Feb 2019)
Investors in Phapros
Phapros has secured backing from 1 investor. Prominent investors backing the company include Kimia Farma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products and healthcare services are manufactured and distributed. | 1817 | kimiafarma.co.id | Jakarta, Indonesia |
Investor details for Phapros
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Phapros
24 people are tracked at Phapros (5 in leadership, 19 in team).
| Name | Role | Group |
|---|---|---|
Emmy Barokah sri Utami | Managing Director | Leadership |
Ida Rahmi Kurniasih | Acting CEO | Leadership |
Yudhi Rangkuti | Director Of Finance, Risk Management And Human Capital | Leadership |
Dewi Arum Sekti | General Manager Production | Leadership |
Santosa Adiwibawa | General Manager Of Production Planning And Inventory Control | Leadership |
Arin Aldian Sinatria | People Development Specialist | Team |
Ayu Dwi Utami | Import Export Specialist | Team |
Bagus Giant | Manager Audit Monitoring | Team |
Dipta Wana Anandita | Logistic And Inventory Control Manager | Team |
Achmad Faiz Falachi | Risk Management And Corporate Governance Manager | Team |
Hc Phapros | Human Capital | Team |
Vemia Apda Wijaya | Account Officer | Team |
Bayu Setiadi | Engineering Manager | Team |
Ferry Andrea | Bugeting Officer | Team |
Fikri Mubarok | Teknisi Preventive Maintenance | Team |
Dhaifan Rabathin Kurniawan | Asset & Investment Monitoring Officer | Team |
Bhisma Akbar Pradana | Manager Integrasi Sistem Mutu | Team |
Fatihatul Alifiyah | Apoteker Dokumentasi Dan Registrasi | Team |
Luthfiyyah Azhari Rachman | Satuan Pengawasan Intern | Team |
Rizqi Saputra | Production Pharmacist | Team |
4 more people are available in the full profile.
Complete people profiles for Phapros
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Phapros
Phapros is a publicly listed company on the IDX with ticker symbol PEHA in Indonesia, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Dec 2018
- Listed onIDX: PEHA
- Listed entityPT Phapros Tbk
- Exchange sectorDistribution services
- ISINID1000147507
- Share price280.00 IDR · 2026-10-14
- Market capitalisation235,200,000,000.00 IDR
- Price to earnings5.7
- EPS (diluted, trailing year)48.74 IDR
- Dividend yield1.8%
- Volume (last session)69,700
Financials of Phapros
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 940.88B IDR | 28.03B IDR | 136.09B IDR |
| 2024 | 744.69B IDR | -285.07B IDR | -190.53B IDR |
| 2023 | 1,000.00B IDR | 7.87B IDR | 116.33B IDR |
| 2022 | 1,170.00B IDR | 28.07B IDR | 147.92B IDR |
| 2021 | 1,050.00B IDR | 11.07B IDR | 146.18B IDR |
Detailed financial statements for Phapros
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Phapros
3 dated milestones of Phapros across 65 years, from founding to its latest funding, stage changes and deals.
- Founded Phapros is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Kimia Farma.
Web traffic of Phapros
The website of Phapros (phapros.co.id) receives about 14.2K visits a month and ranks #1,152,942 among all websites worldwide, #5,758 in Search Engines.
- Monthly visits14.2K
▼ 17.5% vs previous month
- Unique visitors6K
per month
- Global rank#1,152,942
among all websites
- Category rank#5,758
Computers Electronics and Technology · Search Engines
- Bounce rate37%
- Pages per visit4.1
- Average visit4 min 22 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Phapros. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details | |
app.co.id | app.co.id | 96% | #149,837 | – | |
| enseval.com | 95% | 112.3K | #278,738 | View details | |
| pnm.co.id | 93% | 294.4K | #100,055 | View details | |
pharos.co.id | pharos.co.id | 87% | #1,441,996 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Phapros
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Phapros
Phapros was founded in 1954.
Phapros is headquartered in Jakarta, Indonesia. It is registered at Jakarta, Jakarta, Indonesia.
Annual revenue of Phapros is $56.29M as on Dec 31, 2025.
Founded in 1954, Phapros operates in the pharmaceutical sector from Jakarta, Indonesia. Branded and generic prescription drugs, over-the-counter medications, and medical devices are produced across the value chain, including research, development, manufacturing, and distribution. Contract manufacturing services are provided, and products are exported internationally. As a subsidiary of a larger pharmaceutical entity, operations emphasize quality standards in healthcare supplies.
Yes, Phapros is publicly traded on IDX under the ticker symbol PEHA.
Phapros has 1 investor. Key investors include Kimia Farma.
Phapros operates through Pt Phapros Tbk.
Yes. Phapros was acquired by Kimia Farma in February 2019.